Nuclear Receptor Signaling and Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 18222
Special Issue Editor
Interests: regulation of nuclear receptors in human cancer treatment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nuclear receptors (NRs) are a family of transcriptional factors that play a critical role in physiological processes such as reproduction and bone metabolism. NRs are involved in signaling in both nuclear and nonnuclear compartments in response to ligands, growth factors, cytokines, and others, through their crosstalk as well as interaction with other major signal transduction pathways. As a result, NRs convert various extracellular signals into gene expression and various other cellular outcomes, such as cell growth, differentiation, and cell death by environmentally dependent mechanisms.
NRs are involved in every step of cancer, from cancer initiation to cancer growth and further to cancer metastasis and/or clinic prognosis. Moreover, different NRs can cooperate or antagonize the regulation of tumor growth, and the same NRs in different tissues may have a growth-promoting or growth-inhibitory activity dependent or independent of ligands. This Special Issue of Cells welcomes original research papers and review articles in these rapidly developing fields, with the tentative title “Nuclear Receptor Signaling and Cancer”. We hope that this Special Issue will serve as a platform to improve our appreciation of the fascinating roles of NRs in cancer.
Prof. Guan Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nuclear receptors
- signal transduction
- cancer prevention and therapy
- crosstalk of nuclear receptors
- interaction of nuclear receptors with other pathways
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.